US HEALTH CARE REFORM DEBACLE CONTINUES

19 June 1994

Senate Republican Robert Dole reportedly has said he is prepared to block the passage of health care reform, possibly through filibustering, and put the issue at the center of the fall campaign, if Democrats insist on requiring employers to pay for their workers' insurance.

In a later telephone interview with the New York Times, he claimed that he did not use the words "block" or "filibuster," but noted that he would oppose the insurance requirement. When asked specifically about a filibuster for a bill with such a requirement, he said it was too early to discuss that tactic, which would have to be decided on in consultation with colleagues.

At a Republican Committee Northeast regional meeting in Boston, Sen Dole predicted that letting the voters decide the issue in the fall would mean 300 Republic House members and 75 Republican Senators. There are now 178 Republicans of 435 House members, and 44 Republicans among the 100 senators.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight